Mitomycin C CAS NO.:50-07-7
Active Pharmaceutical Ingredients 2025-03-11
CAS NO.:50-07-7
Molecular formula:C15H18N4O5
Molecular weight:334.33
Standard：USP
Content：≥970u/mg
Packaging:100g/Tin
Mitomycin C: A Potent Anticancer Agent
Mitomycin C is an important chemotherapeutic agent used in the treatment of various cancers.
1. General and Pharmacokinetic Information
| Aspect | Details |
| Source | Produced by Streptomyces caespitosus |
| Chemical Class | Alkylating agent |
| Administration | Intravenous injection, can also be used intravesical (for bladder cancer) or intratumoral |
| Distribution | Distributes widely in the body, but shows higher concentration in tumors due to its preferential activation in hypoxic environments |
| Metabolism | Metabolized in the liver by various enzymes, including cytochrome P450 system. Activation in the body is required for its cytotoxic effect |
| Elimination | Excreted mainly in the urine, with a plasma half – life of approximately 1 – 10 hours depending on the route of administration |
2. Mechanism of Action
| Action | Explanation |
| DNA Cross – Linking | Mitomycin C is first reduced to an active form in hypoxic cells. This active form can alkylate DNA, forming cross – links between the two strands of the DNA double helix. The cross – links prevent DNA replication and transcription, leading to cell cycle arrest and ultimately cell death. |
| Free Radical Generation | The activated mitomycin C can also generate free radicals, which can cause oxidative damage to DNA, proteins, and lipids in cells. This additional mechanism contributes to the cytotoxic effect, especially in the presence of oxygen. |
3. Clinical Applications and Adverse Effects
| Category | Details |
| Clinical Applications | Used in the treatment of various solid tumors. In gastric cancer, it is often included in combination chemotherapy regimens. It is also effective in treating bladder cancer (intravesical administration), colorectal cancer, and non – small cell lung cancer. |
| Adverse Effects | Myelosuppression is a common side effect, including neutropenia, thrombocytopenia, and anemia. It can cause renal toxicity, manifested as proteinuria and decreased glomerular filtration rate. Pulmonary toxicity may also occur, presenting as interstitial pneumonitis and pulmonary fibrosis. Gastrointestinal side effects such as nausea, vomiting, and diarrhea are also frequently reported. |
Mitomycin C plays a significant role in cancer treatment, but its use requires careful monitoring due to potential severe side effects.
